Review Home
next story
previous story
HSPH home

ast summer, Dr. JoAnn Manson, MPH'84, DPH'87, was put in an unusual position. as a lead investigator for the women's health initiative and the nurses' health study, she found herself involved with two important studies that had produced apparently conflicting results about postmenopausal hormone therapy (ht) and heart health.

In July 2002, the national Women’s Health Initiative (WHI) terminated its randomized controlled trial of estrogen and progestin because the health risks of the regimen clearly outweighed the benefits. Its most startling finding--that HT increases the risk of heart disease--seemed to contradict the conclusions of several Nurses' Health Study (NHS) reports. During the 1980s and '90s, that observational cohort and several others showed a significant overall reduction in heart disease risk among women taking HT. The end result is an epidemiologic puzzle that Manson and other researchers have only begun to untangle.

"It doesn’t mean that the observational studies were wrong and the clinical trials are right," says Manson, who is a professor at both the Harvard School of Public Health and Harvard Medical School. "Observational studies have been tremendously helpful in generating hypotheses. They are often on target, but in this case there’s a divergence, and we need to get a better understanding of why that is."

A number of School-affiliated scientists are hot on the trail of this understanding. Manson joined Assistant Professor of Epidemiology Francine Grodstein and a non-NHS researcher in penning a February "Sounding Board" article in the New England Journal of Medicine outlining some of the possible reasons behind the disparity. Meir Stampfer, chair of the School's Department of Epidemiology and a NHS investigator, together with Grodstein, organized a major symposium on campus earlier this year to explore the scientific issues raised by the hormone debate. And Dr. Robert Hoover, SD'76, who made the first link between hormone therapy and breast cancer, has been responding to many of the same questions as director of the Epidemiology and Biostatistics Program at the National Cancer Institute (NCI). Their combined efforts are not only critical for women's health but have enormous implications for the design and interpretation of epidemiologic studies in general.

Manson has described the theory that estrogen replacement therapy might protect women from heart disease as a "beautiful hypothesis" generated by the existence of several viable biological mechanisms related to estrogen and the observation that women, prior to menopause, seem to be relatively protected from heart disease. The theory held up when examined through the lens of the NHS, and other studies indicated possible means for the protective effect, including improved cholesterol profiles. But ultimately, those findings didn’t translate into protection from coronary heart disease (CHD) in the WHI.

Often the results of a randomized controlled trial like the WHI would transcend the results of an observational study like the NHS outright--and indeed many doctors and patients have taken its conclusions to heart. But the NHS is not your typical exercise in epidemiology. Researchers believe that nurses, as health workers, are more diligent and precise than the average person in responding to questionnaires and are also more motivated to participate in a study long term. So NHS findings often carry more heft with clinicians and policymakers than other studies of its kind. And more often than not, the results of observational studies correspond with subsequent clinical trials. For many other endpoints--including fractures, stroke, pulmonary embolism, and breast and colon cancers--the NHS predicted the results of the WHI. So why the conflict when it came to CHD?

In looking back, Manson points out several possible biological explanations. Many of the NHS subjects used estrogen alone, while the WHI looked at women taking estrogen/progestin combination therapy. In addition, the two populations may have been different. Compared with WHI subjects, women in the NHS had a lower body-mass index and tended to begin hormones at the time of menopause. Methodologic limitations may have played a role as well, she says. The observational studies may have suffered from a confounding bias--a failure to control adequately for lifestyle or socioeconomic factors, as well as an inability to capture short-term effects of HT. "Every effort should be made to collect information about possible confounders and to control for them carefully in mathematical models," she observes. "But sometimes it is very difficult to control for everything."

Stampfer and Grodstein agree that biology, along with timing, likely contributed to the difference in the two studies. If the women using hormones in the NHS were healthier in ways that could not be controlled for, the data would also have indicated a lower stroke risk. Instead, Grodstein documented a higher stroke risk among HT users in the NHS, a finding that suggests that confounding is unlikely. On the other hand, all three researchers note that the NHS subjects began HT near the onset of menopause, which usually occurs around the age of 50. In contrast, about two- thirds of WHI subjects were over the age of 60 when they entered the study. With that in mind, Stampfer points to animal studies that have shown hormones to protect newly menopausal monkeys from CHD--a protection that failed to appear when therapy was delayed.

So the result may be due to the fact that younger women are less likely to have existing coronary artery disease, Stampfer says. "Hormones increase the production of enzymes that make plaque in the coronary arteries less stable and can cause an acute heart attack," he observes. "If you don’t have plaque, it may not have a bad effect." Studies similar to the WHI in women with preexisting heart disease lend support to this notion, finding that hormone therapy led to more heart attacks, not fewer. Likewise, in the NHS, Grodstein found that women with heart disease who used HT were initially at higher risk for subsequent heart attacks.

Stampfer remarks that each research finding must be weighed both on its own merits and in light of other relevant data. It may mean that hormones protect some women and are too risky for others, but it is very difficult to extrapolate findings from one specific group to other populations. Manson agrees: "One of the lessons here is that researchers need to be very cautious in how they present the results of their findings, noting the strengths and limitations of the research."

Still, there are times when those acting on scientific information have marketing rather than methods in mind. Scientists repeatedly cite the over-promotion of HT by the pharmaceutical industry as one reason women and their doctors believed it could prevent a range of illnesses, including CHD. A 1992 review of 109 HT ads in medical journals found that 40 percent included "unbalanced" information on the drugs' efficacy and side effects, according to a study in the Annals of Internal Medicine.

Since his time at the School, alumnus Robert Hoover has been doing his part to bring a bit more balance to the topic. For his doctoral thesis, he tracked 1,500 women who had started taking estrogen in their mid-40s. The result was the first study to make the link between breast cancer and estrogen, which was published in 1976 in the New England Journal of Medicine and "sparked a whole lot of enthusiasm to go out and do similar studies in larger populations," he says.

Those studies, which came on the heels of research linking estrogen to uterine cancer, convinced a lot of women to stop taking the drugs. But his role did not end there. While a combined estrogen/ progestin therapy seemed to eliminate the uterine cancer risk, Hoover helped determine that the breast cancer risk of that regimen was even higher than with estrogen alone. During a FDA hearing on HT cancer risks in the late 1980s, a participant would make note of his ongoing role in the hormone controversy. "One of the drug company representatives got up to criticize the study and said, 'Whenever we see a study that implies HT is bad, somewhere in the authorship there is this name: Hoover,'" the NCI researcher recalls. At the same time, biological and epidemiologic studies indicated that the drugs might protect against heart disease. "The real question was: do the benefits outweigh the risk?" Hoover says. “That was the driving factor for the WHI."

In light of the study's recent results, it would appear that they don't--at least for women who start hormone use later in life. But that hasn't stopped Hoover, who still works on questions regarding hormones and cancer. (He helped launch the NCI's Cohort Consortium, which will use data and blood samples from a number of large studies--including the NHS. The consortium's first project will examine the link between gene/hormone interactions and breast and prostate cancers.) Today, however, women are advised to take HT only to relieve significant menopausal symptoms and for as short a duration as possible. "It is one of the most dramatic sea changes in clinical medicine that I've ever seen," says Manson.

The good news is when it comes to the heart, we have alternatives, according to Stampfer. "The main take-home message is that we have plenty of ways to prevent heart disease without having to resort to hormones," he says, estimating that about 80 percent of CHD could be prevented by simple changes in lifestyle. "In contrast, we have few ways to lower the risk of breast cancer. So, based on all our past research, avoiding long-term use of estrogen plus progestin makes a lot of sense."

Tinker Ready

Review home
next story
previous story
HSPH home
top of page
This page is maintained by Development Communications in the Office of Resource Development.
To contact us with suggestions, comments, and questions, please e-mail:

Copyright, 2005, President and Fellows of Harvard College